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Intracellular redistribution of b-catenin through mutation of the adenomatous polyposis coli (APC) gene has been proposed as an
early tumorigenic event in most colorectal tumours. In serrated adenoma (SA), a newly recognised subtype of colorectal adenoma,
APC mutations are uncommon, and the contribution of b-catenin to tumorigenesis remains unclear. We compared intracellular
localisation of b-catenin and presence of mutations in exon 3 of b-catenin between 45 SAs, with 71 conventional adenomas (CADs),
and eight carcinomas invading the submucosa (SCAs). Widespread or focal nuclear b-catenin expression was demonstrated in 7% of
SAs (three out of 45), 61% of CADs (43 out of 71), and 88% of SCAs (seven out of eight). Cytoplasmic immunostaining for b-catenin
was demonstrated in 16% of SAs (seven out of 45), 77% of CADs (55 out of 71), and 88% of SCAs (seven out of eight). No
mutation in exon 3 of b-catenin was found in SAs or SCAs, while 7% of CADs (five out of 71) had b-catenin mutations. No nuclear
or cytoplasmic expression of b-catenin was observed in the hyperplastic or conventionally adenomatous epithelium of mixed-type
SAs. These findings suggest that b-catenin mutation is unlikely to contribute to the tumorigenesis in SA, and that intracellular
localisation of b-catenin may not be associated with an early event of the tumour progression in most SAs.
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The adenoma–carcinoma sequence of colorectal carcinogenesis
requires an accumulation of genetic alterations. Inactivation of the
adenomatous polyposis coli (APC) suppressor gene is an initial
event in the development of most colorectal tumours (Kinzler and
Vogelstein, 1996). This inactivation leads to a decrease in APC-
dependent degradation of the oncoprotein b-catenin, thereby
increasing its cytoplasmic abundance (Korinek et al, 1997; Morin
et al, 1997). The b-catenin protein is involved in two functions:
cell-to-cell adhesion and mediation of the Wingless/Wnt signal
transduction pathway (Behrens et al, 1996; Barth et al, 1997); the
latter action is associated with the oncogenic potential of this
protein. This pathway involves stabilisation of the cytoplasmic
pool of b-catenin, translocation of b-catenin to the nucleus,
complex formation between b-catenin and transcription factors of
the T-cell factor (Tcf) family, and activation of this transcriptional
complex resulting in constitutive transcriptional activation of
downstream target genes that regulate cell proliferation or
apoptosis (Korinek et al, 1997; Morin et al, 1997). Recently, c-
myc (He et al, 1998) and cyclin D1 (Tetsu and McCormick, 1999)
have been identified as target genes of the b-catenin/Tcf complex.
Such signal transduction involving b-catenin plays a critical role in
colorectal carcinogenesis.
Recently, mutation in exon 3 of b-catenin has been identified
in approximately half of colorectal tumours that lack APC
mutations (Morin et al, 1997). These b-catenin mutations involve
alterations of exon 3 of serine/threonine sites that normally
are phosphorylated by glycogen synthatase kinese 3b (GSK-3b). As
phosphorylation of these sites is apparently necessary for
APC-induced degradation of b-catenin (Morin et al, 1997), the
b-catenin mutations cause intracellular b-catenin accumulation,
increasing formation of the transcription-activating b-catenin/Tcf
complex.
Some authors recently have reported that hyperplastic colorectal
polyps may in fact be neoplastic lesions because they include some
of the genetic alterations seen in colorectal cancers (CRC), such as
Ki-ras mutations (Otori et al, 1997) and microsatellite instability
(Jass et al, 2000b). Serrated adenoma (SA), which histologically
shows hyperplastic architecture and epithelial dysplasia, has been
recognised as a new subtype of colorectal adenoma (Longacre and
Fenoglio-Preiser, 1990). Given an incidence of high-grade dyspla-
sia in SAs of 10–14.8% (Longacre and Fenoglio-Preiser, 1990;
Matsumoto et al, 1999), SAs have been considered potential
precursors of colorectal carcinoma. Some reports have concluded
that colorectal carcinoma may be associated with SA (Hiyama et al,
1998; Makinen et al, 2001). On the other hand, SAs often occur in
contiguity with typical hyperplastic polyps (Iino et al, 1999). While
some investigators have suggested that genetic alterations in SAs
differ from those in conventional adenomas (CADs) (Ajioka et al,
1998; Hiyama et al, 1998; Uchida et al, 1998; Iino et al, 1999; Jass
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yet al, 2000a; Rashid et al, 2000; Dehari, 2001; Hawkins and Ward,
2001), the differences have not been specified.
Recently, Dehari (2001) and Uchida et al (1998) have reported
that APC gene mutation is uncommon in SA. However, the
contribution of b-catenin to tumorigenesis in SA remains unclear.
The aim of this study was to examine intracellular localisation of
b-catenin and to identify any mutations in exon 3 of b-catenin in
SAs, by comparing the findings with those in CADs and
carcinomas invading the submucosa (SCAs).
MATERIALS AND METHODS
Subjects
A total of 45 SAs from 43 patients who underwent endoscopic
(n¼44) or transanal resection (n¼1) at Showa University
Hospital between September 1997 and December 2001 were
analysed in this study. CADs (n¼71) and SCAs (n¼8) obtained
endoscopically or surgically were studied for comparison.
Informed consent was obtained from all patients. We excluded
patients who had familial adenomatous polyposis, hereditary
nonpolyposis colorectal cancer (HNPCC), or hyperplastic poly-
posis (Jass and Burt, 2000).
Histologic evaluation
Specimens resected or obtained by endoscopy were fixed in 10%
buffered formalin for 24h, dehydrated, and embedded in paraffin.
Serial sections (3mm) were cut from the paraffin block to be
prepared for haematoxylin and eosin (H&E) staining and
immunostaining. All H&E-stained sections were reviewed by a
senior pathologist (TY), who was blinded to colonoscopic findings.
The histologic diagnosis of SA was based on the definition of
Longacre and Fenoglio-Preiser (1990) (Figure 1). Histologic
findings of (1) a serrated architecture simulating a hyperplastic
polyp, (2) goblet cell immaturity, (3) mitotic figures in the upper
crypt zone, (4) prominence of nuclei, and (5) cytoplasmic
eosinophilia were the criteria for inclusion. SAs were subclassified
as pure or mixed depending on whether or not a component other
than SA was present. Epithelial dysplasia without serrated
architecture was classified as CAD. When the tumour cells had
spread through the muscularis mucosae into the submucosa, the
lesion was defined as carcinoma. Clinicopathologic characteristics
of patients with SAs, CADs, and SCAs are shown in Table 1.
No significant difference was noted in the distribution for gender,
age, location, size, or macroscopic type between SA and CAD
groups.
Immunohistochemical detection of b-catenin
Deparaffinised, rehydrated sections were heated in a microwave
oven in 0.01moll
 1 sodium citrate buffer (pH 6.0) for 15min to
retrieve antigens. Endogenous peroxidase activity was inhibited by
incubation with 0.3% hydrogen peroxidase in methanol for 5min.
Sections were incubated with anti-b-catenin antibody (1:300,
Transduction Labs, Lexington, KY, USA) for 90min. Sections were
then incubated with horseradish peroxidase (HRP)-binding
amino-acid polymer for 30min (Histofine Simplestain MAX-PO
kit, Nichrei, Tokyo, Japan). Colour was developed by staining with
diaminobenzidine solution. Sections were lightly counterstained
with haematoxylin. Phosphate-buffered saline (pH 7.2) was used
for rinsing between each step.
Evaluation of b-catenin immunostaining
Each immunostained section was examined under light micro-
scopy and evaluated by a senior pathologist (TY) according to the
modified scoring method of Hugh et al (1999) (Figure 2). Nuclear,
cytoplasmic, and membranous stainings were considered sepa-
rately. Nuclear expression by tumour cells was evaluated as
widespread (475% of cells per section), focal (o75% of cells per
section), or absent (no nuclear staining). Cytoplasmic staining was
evaluated as negative or positive. Staining intensity of the cell
membrane was compared with that seen in normal mucosal cells of
colorectum, and then was scored as: 2þ (preserved type), with
tumour cells displaying well-localised membranous staining
simulating normal mucosa; 1þ (reduced type), with tumour cells
displaying reduced membranous immunoreactivity; 0 (absent
Figure 1 Histologic appearance of a typical SA showing serrated
architecture and epithelial dysplasia. H&E staining.
Table 1 Clinicopathologic characteristics of patients with SAs, CADs,
and SCAs
SAs CADs SCAs
(n¼45) (n¼71) (n¼8)
Gender
M/F 26/17 35/17 5/3
Age 60.0 64.2 60.0
(range) (30–88) (31–83) (51–71)
Location
Left-c 35 47 5
Right-c 10 24 3
Size (mm)
o10 18 39 1
X10 27 32 7
Macroscopic type
Polypoid 36 51 6
Superficial 9 20 2
Histologic dysplasia
LGD 37 51 NA
HGD 8 20
Histology of SA
SA 24 NA NA
SA+HYP 13
SA+CAD 7
SA+SCA 1
SAs¼serrated adenomas; CADs¼conventional adenomas; SCAs¼carcinomas
invading the submucosa; HYP¼hyperplastic polyps; M/F¼male/female; Left-
c¼rectum, sigmoid colon, and descending colon; Right-c¼transeverse colon,
ascending colon, and caecum; LGD¼low-grade dysplasia; HGD¼high-grade
dysplasia; NA¼not applicable.
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epithelial cells were used as an internal control.
DNA preparation from pure-type SA, CAD, and SCA
To extract genomic DNA, five sections (each 5mmt h i c k )w e r e
obtained from an archival block of formalin-fixed, paraffin-
embedded tumour tissue for each polyp type. One section was
stained with H&E, and the percentage of tumour cells was estimated
by microscopic examination. Representative tumour samples
contained a minimum of 80% tumour cells. After deparaffinisation,
DNA samples were extracted from the remaining four sections
using standard proteinase K–phenol–chloroform methods.
Laser-capture microdissection for mixed-type SA
To exclude contamination between tumour types, separate samples
were obtained from mixed-type SAs for adenomatous areas and
other areas (i.e., hyperplastic tissue, conventionally adenomatous
tissue, or carcinomatous tissue) using laser-capture microdissec-
tion. Deparaffinised sections were stained with H&E, followed by
three dehydration steps of 60s each in 70, 95, and 99.5% ethanol,
with final dehydration in xylene. Once air-dried, the stained tissues
were laser-capture microdissected by a PixCell II LCM system
following the manufacturer’s protocols (Acturus Engineering,
Mountain View, CA, USA). After the tumour cells had been
collected into a 0.5-ml reaction tube, DNA was isolated by adding
50ml of proteinase K digestion buffer. The reaction tubes were
incubated overnight at 371C. After denaturation at 951C for 8min,
the lysate was used for DNA analysis.
Detection of b-catenin-gene mutations
Exon 3 of b-catenin was examined for mutations using fluores-
cence-based polymerase chain reaction-single-strand conformation
polymorphism (PCR-SSCP) analysis. Primers used for PCR were 50-
TGATTTGATGGAGTTGGACA-30 (forward) and 50-CTGTTCCCA-
CTCATACAGGA-30 (reverse). The PCR reaction was carried out in
a2 0 ml final volume, containing 50ng DNA, 0.5U Takara Ex Taq
(Takara, Sigma, Japan), 1mmol of each primer, 2.5mM of each
dNTP, and 10 Ex Taq buffer (Takara). The following cycling
protocol was used: 941C for 1min, followed by 40 cycles of 941Cf o r
30s, 551C for 1min, and 721C for 1min, and then a final extension
at 101C for 60min. PCR products were visualised and purified by
electrophoresis on 2% agarose gels for 40min at 100V, and stained
with ethidium bromide. These PCR products were used to detect b-
catenin mutation by fluorescence-based SSCP analysis using an
automated DNA sequencer (ALF Express; Amersham Pharmacia
Biotech, Uppsala, Sweden), with an external cooling bath. Peak
patterns were analysed using the ALFwin Fragment Analyser
program (Amersham Pharmacia Biotech). Shifted peaks indicated
the mutations in the DNA fragments. Nucleotide sequences of DNA
fragments with shifted peaks were determined as described
previously (Makino et al, 2000).
Statistical analysis
To determine statistical significance, relation between molecular
and clinicopathologic data were analysed using w
2 test, or Fisher’s
exact test as appropriate. A value of P less than 0.05 was considered
to indicate significance.
RESULTS
Expression of b-catenin in normal colonic mucosa
Membranous staining of b-catenin uniformly localised at the
intercellular borders was observed in the normal mucosa adjacent
to colorectal neoplasms (Figure 2B). No nuclear or cytoplasmic
immunostaining was seen in normal mucosa.
Nuclear expression of b-catenin
Table 2 shows nuclear expression of b-catenin in SAs, CADs, and
SCAs. No widespread immunostaining was observed in the nuclei
of SA cells, with nuclear expression being restricted to focal areas.
Widespread or focal nuclear expression of b-catenin was demon-
strated in only 7% of SAs (three out of 45), in contrast to 61% of
Figure 2 Immunohistochemical staining of b-catenin. (A) Widespread
nuclear and cytoplasmic expression in a colonic adenoma with high-grade
dysplasia. (B) Membrane expression of b-catenin in the normal mucosa
adjacent to the colorectal neoplasms.
Table 2 Nuclear expression of b-catenin in SAs, CADs, and SCAs
Histology Absent Focal Widespread Total
SAs*
o10mm 18 (100%) 0 0 18
X10mm 24 (89%) 3 (11%) 0 27
CADs*
o10mm 18 (46%) 19 (49%) 2 (5%) 39
X10mm 10 (31%) 19 (59%) 3 (9%) 32
SCAs 1 (12%) 3 (38%) 4 (50%) 8
*Po0.0001. SAs¼serrated adenomas; CADs¼conventional adenomas;
SCAs¼carcinomas invading the submucosa.
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positive for nuclear staining. In SAs and CADs, nuclear expression
of b-catenin was observed more frequently in large (410mm)
than in small (o10mm) lesions. However, these size-related
differences were not statistically significant.
Cytoplasmic and cell-membranous expression of b-catenin
Table 3 shows cytoplasmic expression of b-catenin in SAs, CADs,
and SCAs. Cytoplasmic accumulation of b-catenin was demonstrated
i n1 6 %o fS A s( s e v e no u to f4 5 )a n d7 7 %o fC A D s( 5 5o u to f7 1 :
Po0.0001). All but one SCA specimen was positive for cytoplasmic
staining. In CADs, cytoplasmic immunostaining for b-catenin was
detected more frequently in large (X10mm) than in small
(o10mm) CADs (P¼0.0029). However, no significant difference
was noted in cytoplasmic immunostaining of b-catenin between large
and small SAs. No significant difference in cell-membrane expression
of b-catenin could be found among SAs, CADs, and SCAs.
Detection of b-catenin mutation
No mutation in exon 3 of b-catenin was found in SAs or SCAs,
while 7% of CADs (five out of 71) had b-catenin mutations.
Considering the size of CADs, b-catenin mutations were detected in
8% of small CADs (o10mm; three out of 39) and 6% of large CADs
(410mm; two out of 32). Table 4 summarises tumour location,
tumour size, substitution of one base, codon affected, and predicted
amino-acid substitution. All mutations involved loss of serine or
threonine residues from the GSK-3b phosphorylation region.
Immunohistochemical and genetic findings of b-catenin in
mixed-type SAs
In the 21 mixed-type SAs, serrated and nonserrated areas were
identified histologically as shown in Table 1. The 21 mixed-type
SAs involved various nonserrated components as follows: 13
hyperplastic polyps, seven CAs, and one carcinoma that invaded
the submucosal layer. No nuclear or cytoplasmic immunostaining
for b-catenin was observed in the hyperplastic or conventionally
adenomatous epithelium in the 20 mixed polyps. In the
carcinomatous epithelium of mixed-type SAs, nuclear b-catenin-
positive cells were focally detected, and cytoplasmic staining for b-
catenin was observed (Figure 3). Neither nuclear nor cytoplasmic
staining for b-catenin was found in the adjacent serrated
epithelium. Microdissection allowed each area of mixed-type SA
to be examined separately for a b-catenin mutation. However, no
b-catenin mutation was found in serrated or nonserrated areas.
Table 3 Cytoplasmic expression of b-catenin in SAs, CADs, and SCAs
Histology Negative Positive Total
SAs*
o10mm 16 (89%) 2 (11%) 18
X10mm 22 (81%) 5 (19%) 27
CADs*
o10mm** 14 (36%) 25 (64%) 39
X10mm** 2 (6%) 30 (94%) 32
SCAs 1 (12%) 7 (88%) 8
*Po0.0001; **P¼0.0029. SAs¼serrated adenomas; CADs¼conventional adeno-
mas; SCAs¼carcinomas invading the submucosa.
Table 4 Characteristics of colorectal neoplasms with b-catenin mutation
Sample no. Location Size (mm) Sequence change Codon
Amino-acid
substitution
Small CAD (o10mm)
AD59 T 5 TCT to TTT 45 Ser to Phe
AD60 T 5 TCT to TTT 45 Ser to Phe
AD71 T 3 TCT to TTT 45 Ser to Phe
Large CAD (X10mm)
6207 C 18 TCT to CCT 37 Ser to Pro
4799 Rs 40 TCT to CCT 37 Ser to Pro
CAD¼Conventional adenoma; T¼transverse colon; C¼caecum; Rs¼rectosigmoid.
Figure 3 Immunohistochemical findings in a Dukes’ A carcinoma
associated with SA. The carcinoma invaded the submucosal layer. In (A),
focal nuclear staining of cells for b-catenin is detected; and cytoplasmic
staining for b-catenin is observed in the carcinomatous epithelium of this
mixed-type SA. In (B), neither nuclear nor cytoplasmic staining for b-
catenin is found in the adjacent serrated epithelium.
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Recent reports have described nuclear expression of b-catenin in
familial and sporadic colorectal tumours (Inomata et al, 1996;
Takayama et al, 1996; Hao et al, 1997; Valizadeh et al, 1997; Hugh
et al, 1999; Kobayashi et al, 2000). Valizadeh et al (1997) have
suggested that both cytoplasmic and nuclear localisation of b-
catenin in dysplastic colonic polyps are early events in the
development of colorectal cancer. Nuclear localisation has been
linked to progression of colorectal carcinogenesis when a certain
threshold tumour size is exceeded (Brabletz et al, 2000). However,
Kobayashi et al (2000) have reported that nuclear translocation of
b-catenin is involved in initiation of cancer in distinction to
adenoma, independently of APC mutations. In our study, about
80% of CADs displayed either cytoplasmic or nuclear localisation
of b-catenin, while nuclear overexpression was observed in 50% of
SCAs (four out of eight). Abnormal distribution of b-catenin was
detected more frequently in large CADs (X10mm) than in smaller
CADs. However, nuclear overexpression of b-catenin generally was
not observed in our SAs; even focal nuclear staining was found in
only 7% (three out of 45). Cytoplasmic accumulation of b-catenin
was observed in 16% of SAs (seven out of 45). The nuclear and
cytoplasmic localisation of b-catenin in SA thus differs from
observations in CADs and SCAs.
We identified mutations in exon 3 of b-catenin in 7% of sporadic
CADs (five out of 71). As in previous studies (Kitaeva et al, 1997;
Morin et al, 1997; Sparks et al, 1998; Samowitz et al, 1999), all
mutations involved the loss of serine or threonine residues from
GSK-3b phosphorylation sites. Loss of these phosphorylation sites
is thought to promote tumorigenesis through decreased APC-
associated degradation of b-catenin and increased b-catenin/Tcf
transcriptional activation (Morin et al, 1997).
One important reported finding in CADs is a difference in the
incidence of b-catenin mutation between small and large CADs.
Samowitz et al (1999) have suggested that adenomas with mutations
in exon 3 of b-catenin are unlikely to progress to large adenomas or
invasive cancers, since b-catenin mutations are significantly more
common in very small adenomas than in large adenomas or invasive
cancers. Mutations in b-catenin sometimes were seen in our large
CADs as well as small CADs, with no significant difference in
frequency according to lesion size (small, 6%; large, 8%). This
disagreement with the previous study (Samowitz et al, 1999) suggests
that mutation of b-catenin may be an early, nonsize-dependent event
in the conventional adenoma–carcinoma sequence.
b-Catenin mutation occurs in primary CRC and CRC cell lines
that lack APC mutation (Morin et al, 1997). APC mutation is
infrequent in MSI-H cancers (Konishi et al, 1996; Salahshor et al,
1999). However, b-catenin mutation is not found in sporadic CRC
with high level of microsatellite instability (MSI-H) (Salahshor et al,
1999). These observations fit with the lack of abnormal b-catenin
immunostaining in sporadic MSI-H cancers (Wong et al, 2002).
When b-catenin mutation is found in sporadic MSI-H cancers, the
subjects are young and probably have HNPCC (Mirabelli-Primdahl
et al, 1999). Moreover, Mirabelli-Primdahl et al (1999) have
reported that b-catenin mutation is not found in 27 samples of
microsatellite stable CRC. It can therefore be inferred that b-
catenin mutation is implicated in only a very small proportion of
CRC that may be a subset of HNPCC cases.
Recent experimental and clinical analyses have indicated that
cytoplasmic expression and nuclear translocation of b-catenin in
colorectal tumour cells usually results from mutations in the APC
or b-catenin genes (Morin et al, 1997; Rubinfeld et al, 1997;
Iwao et al, 1998). Unregulated intracellular b-catenin protein
has been shown to activate its target gene expression by the
complex formation with a family of nuclear transcription factors.
APC mutations are present in about 80% of sporadic colorectal
adenomas and cancers, while in recent studies (Uchida et al,
1998; Dehari, 2001), APC mutations have been rare in SAs. We
observed no mutation of b-catenin in SAs. Nuclear or cytoplasmic
expression of b-catenin was significantly less common in SAs
than in CADs or SCAs. Furthermore, no nuclear or cytoplasmic
immunostaining of b-catenin was observed in adjacent hyperplas-
tic or conventionally adenomatous glands in mixed-type
SAs. Thus, the signalling pathway involving APC and b-
catenin seems unlikely to be important for tumorigenesis in most
SAs.
The previous study (Samowitz et al, 1999) has suggested that b-
catenin mutation occurs in a small subset of CAD, and CAD
initiated by b-catenin mutation may rarely progress to CRC. From
the preceding observation, it can be deduced that b-catenin is not
implicated in the initiation of SAs, or that SAs rarely progress to
carcinoma. We demonstrated that no mutation of b-catenin was
detected in SAs. Furthermore, when we separately examined b-
catenin mutation in serrated and nonserrated areas of mixed-type
SAs, no b-catenin mutation was found in either area. Thus,
mutations in exon 3 of b-catenin are unlikely to contribute to
tumorigenesis in SA. In fact, it has been previously shown that b-
catenin and APC mutations are uncommon in SAs (Sawyer et al,
2002). This supports the suggested role of SAs in the pathogenesis
of sporadic MSI-H cancer.
We found one mixed-type SA with two histologically distinct
areas representing carcinoma and SA. Although focally nuclear
expression of b-catenin was demonstrated in the carcinomatous
component of this lesion, cytoplasmic accumulation of b-catenin
was observed. Neither nuclear nor cytoplasmic staining was found
in the adjacent serrated epithelium. The immunohistologic
heterogeneity demonstrated in this tumour implies that intracel-
lular redistribution of b-catenin might be a late event in the
development of colorectal cancer. However, only one such case of
carcinoma associated with SA was analysed in this study, so
further investigation of these genetic changes is required to clarify
the mechanism of tumorigenesis in SA.
In summary, we evaluated the status of b-catenin in the
development of SA using immunohistochemical and genetic
methods. Intracellular localisation of b-catenin in SAs differed
from that in CADs or SCAs, and no b-catenin mutation was
observed in SAs. We concluded that b-catenin mutation is unlikely
to contribute to tumorigenesis in SA. Further, intracellular
localisation of b-catenin may not be associated with an early
tumorigenic event in most SAs.
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